Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Adial Pharmaceuticals, Inc. (ADIL)

0.4092   -0.006 (-1.4%) 03-22 12:06
Open: 0.4125 Pre. Close: 0.415
High: 0.435 Low: 0.4
Volume: 47,262 Market Cap: 12(M)

Technical analysis

as of: 2023-03-22 11:44:10 AM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 0.57     One year: 0.7
Support: Support1: 0.31    Support2: 0.25
Resistance: Resistance1: 0.48    Resistance2: 0.6
Pivot: 0.43
Moving Average: MA(5): 0.41     MA(20): 0.44
MA(100): 0.33     MA(250): 0.74
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 36     %D(3): 35.5
RSI: RSI(14): 48.2
52-week: High: 2.26  Low: 0.2
Average Vol(K): 3-Month: 768 (K)  10-Days: 610 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ADIL ] has closed above bottom band by 36.0%. Bollinger Bands are 48.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.46 - 0.46 0.46 - 0.46
Low: 0.4 - 0.4 0.4 - 0.4
Close: 0.41 - 0.42 0.42 - 0.42

Company Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Headline News

Tue, 21 Mar 2023
Adial Pharmaceuticals (ADIL) Engages The Keswick Group to ... -

Wed, 08 Mar 2023
Why Rigel Pharmaceuticals Shares Are Trading Higher By Over 30 ... - UK

Wed, 08 Mar 2023
Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th - Yahoo Finance

Tue, 07 Mar 2023
Why Rivian Automotive Shares Are Trading Lower By Over 10 ... - UK

Tue, 07 Mar 2023
Meta's stock up on report of more layoffs, and WeightWatchers telehealth deal gives it access to promising obesity drug market - MarketWatch

Mon, 06 Mar 2023
Is it Time to Dump Adial Pharmaceuticals Inc (ADIL) Stock After it Has Fallen 6.67% in a Week? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 29 (M)
Shares Float 23 (M)
% Held by Insiders 46.5 (%)
% Held by Institutions 19.1 (%)
Shares Short 382 (K)
Shares Short P.Month 134 (K)

Stock Financials

EPS -0.65
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.2
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -99.5
Return on Equity (ttm) -249
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.51
Qtrly Earnings Growth 0
Operating Cash Flow -12 (M)
Levered Free Cash Flow -6 (M)

Stock Valuations

PE Ratio -0.63
PEG Ratio 0
Price to Book value 2.04
Price to Sales 0
Price to Cash Flow -0.99

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.